SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, BCMA, CAR-T, CD19

Allogene Doses First Patients With ALLO-316 (CD70 CAR-T) and Presents Novel TurboCARs for Solid Tumors; bluebird’s Oncology Newco Renamed as 2seventy bio; Allogene and bluebird bio Q1 2021 Earnings Call Summaries

Here is a brief preview of this blast: On Wednesday, May 5, Allogene held their Q1 2021 earnings call (press release) highlighting the initiation of ALLO-316’s Ph1 TRAVERSE trial in renal cell carcinoma (RCC) and provided several updates across their CAR-T programs. On the same day, bluebird bio reported their Q1 2021 results (press release) and confirmed that the oncology Newco will be called 2seventy while highlighting Abecma’s FDA approval in ≥5L MM. Below, Celltelligence provides insights on how Allogene may strategically advance their CAR-T programs while discussing Allogene’s growing potential in the solid tumor setting with their TurboCAR platform. Furthermore, Celltelligence will discuss 2seventy bio's corporate structure while commenting on Abecma’s potential EU approval timeline.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.